Plasma Clearance and Immunologic Properties of Long-Acting Superoxide Dismutase Prepared Using 35,000 to 120,000 Dalton Poly-Ethylene Glycol

  • Mark G. P. Saifer
  • Ralph Somack
  • L. David Williams
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 366)


Some biological properties of bovine and recombinant human Cu, Zn superoxide dismutase (bSOD and rhSOD)-poly-ethylene glycol (PEG) adducts prepared by coupling 1–9 strands of high molecular weight PEG (35,000–120,000 daltons) are compared to SOD adducts coupled with 7 or 15 strands of low molecular weight PEG (5,000 daltons).

Plasma clearance after i.v. injection was measured in mice and dogs. Conjugates of bSOD with 2 strands of PEG 40,000, 3 strands of PEG 72,000 or 1 strand of PEG 100,000 demonstrated half-lives of about 36 hours in mice, whereas the half-life of a conjugate with 7 strands of PEG 5,000 was about 24 hours. A PEG-bSOD with an average of 3.3 strands of PEG 41,000 was cleared from plasma with a terminal half-life of 36 to 48 hours after intraperitoneal injection in mice. PEG-SODs prepared from bSOD and rhSOD with 3 strands of PEG 50,000 each had plasma half-lives of approximately five days in dogs.

An enzyme immunoassay (ELISA) was employed to measure cross-reactivity with a rabbit antibody directed against bSOD. A series of bSOD adducts with 2 to 9 strands of PEG 35,000–120,000 were compared to PEG-bSODs with 7 or 15 strands of PEG 5,000. Attaching larger PEG strands was at least 3 times more effective in reducing antigenicity, compared to PEG 5,000.

Ability to induce sensitizing antibodies was measured using subcutaneous sensitization followed by i.v. or s.c. challenge in mice. Some bSOD conjugates with either 7 or 15 strands of PEG 5,000 induced sensitization reactions before the sixth challenge. Fewer than 1 % of the animals tested with bSOD or rhSOD adducts with 3 or 4 strands of PEG 65,000, or 3 strands of PEG in the 30,000–50,000 molecular weight range, showed signs of anaphylaxis during six or seven challenges.

In a passive cutaneous anaphylaxis test (optimized to measure mouse IgE), neither bSOD coupled to 2 strands of PEG 120,000 nor bSOD coupled to 9 strands of PEG 35,000 induced detectable antibodies against either of these PEG-bSOD preparations or against bSOD; however, the adduct with 2 strands of PEG 120,000 reacted weakly with pre-formed antibodies to bSOD. The high molecular weight PEG-bSODs tested were not immunogenic, but were weakly antigenic, compared to bSOD.

Key Words

Long-acting superoxide dismutase SOD PEG PEG-SOD 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. Huber and K.B. Menander-Huber (1980) Orgotein. Clinics in Rheumatic Diseases, 6:465–497.Google Scholar
  2. 2.
    F.F. Davis, A. Abuchowski, T. van Es, N.C. Palczuk, K. Savoca, R. H-L. Chen and P. Pyatak (1980) Soluble, nonantigenic polyethylene glycol-bound enzymes. In Biomedical Polymers, Polymeric Materials and Pharmaceuticals for Biomedical Use (E.P. Goldberg and A. Nakajima, eds.), Academic Press, London, pp. 441–442.Google Scholar
  3. 3.
    F.F. Davis, A. Abuchowski, T. van Es, N.C. Palczuk, H-L. Chen, K. Savoca and K. Wieder (1978) Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. In Enzyme Engineering, Vol. 3, (G.B. Braun, G. Manecke and L.B. Wingard, Jr., eds.), Plenum Press, New York, pp. 169–173.CrossRefGoogle Scholar
  4. 4.
    P.S. Pyatak, A. Abuchowski and F.F. Davis (1980) Preparation of a polyethylene glycol-superoxide dismutase adduct and an examination of its blood circulating life and antiinflammatory activity. Research Communications in Chemical Pathology and Pharmacology, 29:113–127.PubMedGoogle Scholar
  5. 5.
    F.M. Veronese, R. Largajolli, E. Boccù, C.A. Benassi and O. Schiavon (1985) Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase. Applied Biochemistry and Biotechnology, 11:141–152.PubMedCrossRefGoogle Scholar
  6. 6.
    E. Boccù, R. Largajolli and F.M. Veronese (1982) Coupling of monomethoxy-poly-ethyleneglycols to proteins via active esters. Zeitschrift für Naturforschung, 38c:94–99.Google Scholar
  7. 7.
    E. Boccù, G.P. Velo and F.M. Veronese (1982) Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase. Pharmacological Research Communications, 14:113–120.PubMedCrossRefGoogle Scholar
  8. 8.
    R. Somack, M.G.P. Saifer and L.D. Williams (1991) Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000–72,000 daltons). Free Radical Research Communications, 12–13:553–562.PubMedCrossRefGoogle Scholar
  9. 9.
    J.M. McCord and I. Fridovich (1969) Superoxide dismutase. An enzymatic function for erythrocuprein (hemocuprein). Journal of Biological Chemistry, 244:6049–6055.PubMedGoogle Scholar
  10. 10.
    M. Leonard, J. Neel and E. Dellacherie (1984) Synthesis of monomethoxy-polyoxyethylene-bound haemoglobins. Tetrahedron, 40:1581–1584.CrossRefGoogle Scholar
  11. 11.
    C.O. Beauchamp and I. Fridovich (1971) Improved assays and an assay applicable to acrylamide gels. Analytical Biochemistry, 44:276–287.PubMedCrossRefGoogle Scholar
  12. 12.
    Y. Sun, L. W. Oberley and Y. Li (1988) A simple method for clinical assay of superoxide dismutase. Clinical Chemistry, 34:497–500.PubMedGoogle Scholar
  13. 13.
    Z. Ovary (1964) Passive cutaneous anaphylaxis. Immunological Methods (J.F. Ackroyd, ed.), Blackwell, London, pp. 259–283.Google Scholar
  14. 14.
    C.O. Beauchamp, S.L. Gonias, D.P. Menapace and S.V. Pizzo (1983) A new procedure for the synthesis of polyethylene glycol-protein adducts: effects on function, receptor recognition and clearance of superoxide dismutase, lactoferrin and α2-macroglobulin. Analytical Biochemistry, 13:25–33.CrossRefGoogle Scholar
  15. 15.
    J.M. McCord and K. Wong (1979) Phagocyte-produced free radicals: roles in cytotoxicity and inflammation. In Ciba Foundation Symposium, Vol 65, Excerpta Medica, Amsterdam, pp. 343–360.Google Scholar
  16. 16.
    K. Grankvist, S. Marklund and I-B. Täljedal (1981) Superoxide dismutase is a prophylactic against alloxan diabetes. Nature, 294:158–160.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Mark G. P. Saifer
    • 1
  • Ralph Somack
    • 2
  • L. David Williams
    • 1
  1. 1.DDI Pharmaceuticals, Inc.Mountain ViewUSA
  2. 2.Applied BioSystems, Inc.Foster CityUSA

Personalised recommendations